Allarity Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALLR research report →
Price Chart
About the company
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics.
- CEO
- Thomas H. Jensen
- IPO
- 2021
- Employees
- 8
- HQ
- Tarpon Springs, FL, US
Get TickerSpark's AI analysis on ALLR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.75M
- P/E
- -1.83
- PEG
- -0.01
- P/S
- 65.95
- P/B
- 6.43
- EV/EBITDA
- -2.53
- Div Yield
- 0.00%
- Gross Margin
- 107.54%
- Op Margin
- -3128.99%
- Net Margin
- -3575.07%
- ROE
- -152.77%
- ROIC
- -41.81%
Latest fiscal year · YoY change
- Revenue
- $320.00K+0.0%
- Gross Profit
- $320.00K+0.0%
- Op Income
- $-12,605,000
- Net Income
- $-11,231,000+54.2%
- EPS
- $-0.78+95.1%
- OCF Growth
- +14.6%
- FCF Growth
- +16.0%
- 52W High
- $2.35
- 52W Low
- $0.77
- 50D MA
- $1.30
- 200D MA
- $1.23
- Beta
- 0.51
- RSI (14)
- 61
- Avg Volume
- 143.60K
No earnings-call transcripts are available for ALLR yet.
- Free Float
- 76.3%
- Shares Outstanding
- 15.91M
- Float Shares
- 12.14M
of shares held by institutions
8 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 4 ETFs
Biggest fund positions in ALLR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 28, 26 | Jensen Thomas | other | 200,000 |
| Jan 7, 26 | Hoeiland Jesper | other | 25,000 |
| Jun 10, 25 | Hoeiland Jesper | other | 0 |
| Jan 28, 26 | McLaughlin Gerald W. | other | 45,000 |
| Jan 28, 26 | Graff Jeremy R. | other | 133,333 |
| Jan 28, 26 | Ervin Jeffrey S | other | 150,000 |
| Jan 7, 26 | Graff Jeremy R. | other | 133,333 |
| Sep 30, 25 | Graff Jeremy R. | other | 39,494 |
| Sep 30, 25 | Graff Jeremy R. | other | 39,494 |
| Sep 30, 25 | Graff Jeremy R. | other | 14,613 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALLR coverage
Recent articles, reports, and earnings notes.
No research on ALLR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALLR report →Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
globenewswire.com · Aug 14
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
zacks.com · Jul 22
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
globenewswire.com · Jul 7
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
zacks.com · Jul 6
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
globenewswire.com · Jun 30
Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com · Jun 26
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
zacks.com · Jun 19
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
globenewswire.com · Jun 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.